Anapsos

N/A

Report date: 2022/02/24 13:58:38
NME

Base Information

Drug NameAnapsos
Drug Alias NameCalagualinePolypodium leucotomos extractPsoriacenEQA-00
ClassificationNatural product/ExtractSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear factor NF-kappa-B complex inhibitors
TargetsNuclear factor NF-kappa-B complex
Therapy Area/IndicationsPsoriasisDermatitis, Atopic
Global Approved IndicationsPsoriasisDermatitis, Atopic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved Date1972/01/01
Country/TerritoryN/A
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAsac Pharmaceutical International
China Registration ClassN/A

Develop Information

Active CompaniesAsac Pharmaceutical International
Inactive CompaniesN/A
Active IndicationsPsoriasisDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeD11AH
Related LinksN/A